Product Name:
SMARCA4-pS610+pS613
Product Number:
ab-pn726
Target Full Name: Transcription activator BRG1
Target Alias: Brahma 1; BRG1; BRG-1; EC 3.6.1.-; Global transcription activator SNF2L4; SMCA4; SN24; SNF2B; SNF2-beta; SNF2L4
Product Type Specific: SMARCA4 phosphosite-specific antibody
Antibody Code: PN726
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S610+S613
Protein UniProt: P51532
Protein SigNET: SMARCA4
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human SMARCA4
Antibody Immunogen Sequence: DET(pS)QM(pS)DLP(βA)C
Antibody Immunogen Description: Corresponds to amino acid residues D607 to P616. The effects of S610 and S613 phosphorylation are unclear. These are the major sites of in vivo phosphorylation based on ≥56 and ≥69 mass spectrometry reports, respectively, in PhosphoSitePlus.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.8 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Dog | Rat | Chicken | Zebra fish.
Related Product 1: SMARCB1 T134 phosphorylation antibody (Cat. No.: AB-PN727)
Scientific Background: SMARCA4 (Transcription activator BRG1) is a 185–205 kDa ATP-dependent catalytic subunit of the SWI/SNF complex, which remodels chromatin to regulate gene expression in the nucleus of cells. It belongs to the neural progenitor-specific and the neuron-specific chromatin remodeling complexes (npBAF and nBAF, respectively). As a core ATPase subunit, it uses ATP to alter nucleosome structure, facilitating DNA transcription and repair and cell cycle control and differentiation. It Interacts with p53 and the androgen receptor, regulating gene expression to prevent uncontrolled cell growth. It is a component of remodeling complexes including Swi/Snf-A (BAF), Swi/Snf-B (PBAF), Brm, WINAC and Brg1. Each complex contains a catalytic subunit (either SMARCA4 or SMARCA2), and at least SMARCE1, BAF53A or BAF53B, SMARCC2 and SMARCB1. SWI/SNF complexes are required for mammalian development and are mutated in ~20% of all human primary tumours. It is a transcriptional coactivator of nuclear hormone receptors. It colocalizes with ZEB1 in stroma of normal colon as well as in de-differentiated epithelial cells at the invasion front of colorectal carcinomas. It acts as a corepressor of ZEB1 to regulate E-cadherin transcription and is required for induction of epithelial-mesenchymal transition (EMT) by ZEB1. It can bind BRCA1, as well as regulate the expression of the Tumorigenic protein CD44. SMARCA4, in consort with ZEB1, represses the transcription of E-cadherin and promotes the epithelial-to-mesenchymal transition (EMT). It is required for stem cell maintenance in the mouse intestinal epithelium. Its loss inhibits aberrant Wnt-signaling and prevents tumorigenesis in the mouse small intestine. Mutations or deficiencies in SMARCA4 are linked to aggressive cancers, Smarca4-deficient thoracic sarcomas and Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT). Mutations also cause rhabdoid tumour predisposition syndrome (RTPS2) and Coffin-Siris syndrome. This description may include information annotated by UniProt and/or Google AI.